Gene therapy

After decades of research – much of it funded by the public - gene therapy is a reality. Now high costs are blocking patient access. Prices should be constrained

New report shows how long term investment in novel products like cell and gene therapies is beginning to bear fruit. The concern now is the price of these products and ensuring patients get access

More than a year after the public consultation closed, EMA and the Commission have announced moves that aim to clear the regulatory logjam holding back commercialisation of therapies based on tissues, cells and genes